Assessing Direct Oral Anticoagulants in the Clinical Laboratory

Abstract

Direct oral anticoagulants (DOACs) have significant advantages over vitamin K antagonists including lack of need for routine laboratory monitoring. However, assessment of DOAC effect and concentration may be important to guide clinical management including need for DOAC reversal, particularly in acute or emergent situations. In this manuscript, the authors describe tests to screen for DOAC presence and tests that have demonstrated equivalence to gold standard testing for quantifying DOAC exposure. They also discuss the effect of DOACs on other coagulation assays and strategies for monitoring unfractionated heparin in patients with concomitant DOAC exposure.

Keywords: Anti-Xa; Apixaban; Dabigatran; Direct oral anticoagulants (DOACs); Edoxaban; Laboratory; Rivaroxaban.